enGene Q1 net loss $29.8M; cash $312.5M; LEGEND data update at spring 2026 conference

enGene Therapeutics Inc.

2026-Q1 EPS reported $0.44

Net loss $29.8M ($0.44/share) vs $24.6M ($0.48/share) year ago; operating expenses $31.2M.
Cash & marketable securities $312.5M; expected runway into 2H 2028.
Expanded Hercules Capital debt facility to $125M for detalimogene development & commercial prep.
LEGEND pivotal cohort 63% CR at any time (n=62); BLA filing planned for 2H 2026.
12-month CR data expected 2H 2026; CDRP program selected by FDA.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.